Request Demo
Last update 12 May 2025
Haemophilus b conjugate vaccine(GSK Plc)
Last update 12 May 2025
Overview
Basic Info
Drug Type Prophylactic vaccine, Toxoid vaccine, Conjugated vaccine |
Synonyms Hib vaccine conjugate(GSK Plc), Hiberix, GSK 208108 |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (19 Aug 2009), |
Regulation- |
Login to view timeline
Related
21
Clinical Trials associated with Haemophilus b conjugate vaccine(GSK Plc)NCT03893448
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants (PNEU-PED)
NCT03620162
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13™ With Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-DIRECTION)
NCT03621670
Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants
100 Clinical Results associated with Haemophilus b conjugate vaccine(GSK Plc)
Login to view more data
100 Translational Medicine associated with Haemophilus b conjugate vaccine(GSK Plc)
Login to view more data
100 Patents (Medical) associated with Haemophilus b conjugate vaccine(GSK Plc)
Login to view more data
186
Literatures (Medical) associated with Haemophilus b conjugate vaccine(GSK Plc)31 Jan 2025Open Forum Infectious Diseases
Real-World Effectiveness of 3 Types of Acellular Pertussis Vaccines Among Children Aged 3 Months–16 Years in Lu’an, China: A Matched Case-Control Study
Article
Author: Qin, Wei ; Zhang, Huan ; Tian, Yongjie ; Ma, Bingxin ; Ma, Liguo ; Zhao, Changjun ; Liu, Yongyu ; Pan, Fan ; Zhou, Yu ; Wang, Yao ; Chen, Yafei
Abstract:
Background:
The real-world vaccine effectiveness (VE) of the diphtheria, tetanus, and acellular pertussis (DTaP), DTaP–Haemophilus influenzae type b (Hib), and DTaP–inactivated polio (IPV)/Hib vaccines has not been thoroughly evaluated in China. Additionally, there are limited data on the VE of acellular pertussis–containing vaccines (aPVs) when used interchangeably.
Methods:
We conducted a matched case-control study to estimate the VE of aPVs against polymerase chain reaction–confirmed pertussis infection in Lu’an in 2024. A conditional logistic regression model was used to compare the odds ratios (ORs) of vaccination between cases and controls. VE was calculated as [(1 – adjusted OR) × 100%], and 95% confidence intervals (CIs) were computed around the estimates.
Results:
A total of 1936 children aged 3 months to 16 years were included in the study. The overall VE was 77.3% (95% CI, 35.2%–92.1%). The VE for fully vaccinated children was 88.4% (95% CI, 57.3%–96.8%), while the VE for partially vaccinated children was 77.4% (95% CI, 35.5%–92.1%). The VE of DTaP, DTaP-Hib, and DTaP-IPV/Hib was 75.8% (95% CI, 29.7%–91.7%), 83.2% (95% CI, 47.8%–94.6%), and 79.8% (95% CI, 36.5%–93.6%), respectively. Compared with mixed vaccination (65.3%.), the incremental VE of DTaP, DTaP-Hib, and DTaP-IPV/Hib was 31.0% (95% CI, 1.0%–51.9%), 52.9% (95% CI, 19.1%–72.6%), and 41.1% (95% CI, −18.7% to 71.8%), respectively. We observed a decline in VE over time, decreasing from 76.5% (95% CI, 33.0%–91.7%) within the first 2 years to −5.5% (95% CI, −495.2% to 81.3%) after 6 years or more.
Conclusions:
All aPVs provide significant protection against pertussis infection, although this protection wanes over time. The VE appears to decrease materially if these vaccines are administered alternately in an individual's routine immunization schedule.
31 Dec 2024Human Vaccines & Immunotherapeutics
Adverse events following immunization of co- and separate administration of DTaP-IPV/Hib vaccines: A real-world comparative study
Article
Author: Li, Jing ; Zhu, Yiqing ; Wang, Yihan ; Guo, Yu ; Wang, Yafei ; Wang, Jinghui ; Wang, Lina ; Sun, Li
To fully understand the safety of DTaP-IPV/Hib vaccination, we evaluated the differences between DTaP-IPV/Hib co-administration and separate administration of the DTaP, IPV and Hib vaccines (DTaP+IPV+Hib) based on adverse events following immunization (AEFI). All AEFI reported in Hebei Province, China, between 2020 and 2022 were included in this study. The risk difference (RD%), relative risk (RR), and Chi-square value were used to compare the differences in reported rates of AEFI between the DTaP-IPV/Hib and DTaP+IPV+Hib groups. From 2020 to 2022, 130 AEFI cases were reported in Hebei Province after DTaP-IPV/Hib vaccination, corresponding to an AEFI reported rate of 66.9/million doses, which was significantly lower than that for DTaP+IPV+Hib (9836 AEFI with a reported rate of 637.8/million doses). The overall reported rate of non-severe AEFI for DTaP+IPV+Hib vaccines was 9.5 times that of DTaP-IPV/Hib vaccination [95% confidence interval (CI): 8.0, 11.3]. Meanwhile, the reported rate of AEFI among infants aged 0-1 y was 9.8 times higher for DTaP+IPV+Hib than for DTaP-IPV/Hib (95% CI: 8.2, 11.7). DTaP+IPV+Hib vaccination also resulted in higher risks of high fever, localized redness and swelling, localized induration, and allergic rash compared with DTaP-IPV/Hib vaccination. The risk of AEFI, which were mostly mild reaction, was higher after vaccination with DTaP+IPV+Hib than after DTaP-IPV/Hib vaccination.
01 Dec 2024The Lancet regional health. Southeast Asia
Routine immunization against Streptococcus pneumoniae and Haemophilus influenzae type B and antibiotic consumption in India: a dynamic modeling analysis
Article
Author: Parameswaran, Giridara Gopal ; Gleason, Alec C ; Klein, Eili ; Laxminarayan, Ramanan ; Kumar, Chirag K ; Gleason, Alec C. ; Nandi, Arindam ; Summan, Amit ; Kumar, Chirag K.
Background:
Childhood vaccinations can reduce disease burden and associated antibiotic use, in turn reducing the risk of antimicrobial resistance (AMR). We retrospectively estimated the population-level reductions in antibiotic use in India following the introduction of vaccines against Streptococcus pneumoniae and Haemophilius influenzae type B in the national immunization program for children in the mid-2010s and projected future gains to 2028 if vaccination coverage were to be increased.
Methods:
Using IndiaSim, a dynamic agent-based microsimulation model (ABM) for India, we simulated the spread of Streptococcus pneumoniae and Haemophilius influenzae type B (Hib) among children to estimate reductions in antibiotic use under the scenarios of: (i) pneumococcal and Hib vaccine coverage levels equivalent to the national coverage of pentavalent diphtheria-pertussis-tetanus third dose (DPT3) compared to a baseline of no vaccination, and (ii) near-universal (90%) coverage of the vaccines compared to pre-COVID national DPT3-level coverage. Model parameters, including national DPT3 coverage rates, were based on data from the National Family Household Survey 2015-2016 and other published sources. We quantified reductions in antibiotic consumption nationally and by state and wealth quintiles.
Findings:
We estimate that coverage of S. pneumoniae and Hib vaccines at the same level as DPT3 in India would translate to a 61.4% [95% UI: 43.8-69.5] reduction in attributable antibiotic use compared to a baseline of zero vaccination coverage. Increases in childhood vaccination coverage between 2004 and 2016 have likely reduced attributable antibiotic demand by as much as 93.4% among the poorest quintile. Increasing vaccination coverage by an additional 11 percentage points from 2016 levels results in mortality and antibiotic use across wealth quintiles becoming increasingly similar (p < 0.05), reducing in health inquities. We project that near-universal vaccine coverage would further reduce inequities in antibiotic demand and may eliminate of outbreak-associated antibiotic use from S. pneumoniae and Hib.
Interpretation:
Though vaccination has a complex relationship with antibiotic use because both are modulated by socioeconomic factors, increasing vaccinations for S. pneumoniae and Hib may have a significant impact on reducing antibiotic use and improving health outcomes among the poorest individuals.
Funding:
The Bill & Melinda Gates Foundation (grant numbers OPP1158136 and OPP1190803).
100 Deals associated with Haemophilus b conjugate vaccine(GSK Plc)
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Haemophilus Infections | United States | 19 Aug 2009 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Rotavirus Infections | Phase 3 | United States | 14 Sep 2017 | |
| Viral gastroenteritis due to Rotavirus | Phase 3 | United States | 14 Sep 2017 | |
| Streptococcal Infections | Phase 3 | United States | 10 Jun 2008 | |
| Meningococcal Infections | Phase 3 | Philippines | 16 Jun 2005 | |
| Meningococcal Infections | Phase 3 | Thailand | 16 Jun 2005 | |
| Diphtheria | Phase 3 | - | 01 Sep 2000 | |
| Hepatitis B | Phase 3 | - | 01 Sep 2000 | |
| Poliomyelitis | Phase 3 | - | 01 Sep 2000 | |
| Tetanus | Phase 3 | - | 01 Sep 2000 | |
| Whooping Cough | Phase 3 | - | 01 Sep 2000 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 3 | 1,280 | (HRV Porcine Circovirus (PCV)-Free Liquid Group) | cvbjfiodsv = zvbojezxnj mbecspaslm (bkaulesyfd, rzhyeajnyb - uxykpduwea) View more | - | 31 Oct 2019 | ||
(HRV Lyophilized Group) | cvbjfiodsv = gsbsqunvtr mbecspaslm (bkaulesyfd, lzmicayykp - nzzcyypscb) View more | ||||||
Phase 2 | 301 | (SB692342 2 Dose Group) | qbwksyfiub = rzviglbvas yevrxfwfov (vowmhxpwhn, ctjjvwmulf - ubqdcjnlqq) View more | - | 27 Nov 2018 | ||
(SB692342 1 Dose Group) | qbwksyfiub = ncguzebqjl yevrxfwfov (vowmhxpwhn, utgauezvtx - yokagpkcjw) View more | ||||||
Phase 3 | 296 | (Tritanrix-HepB/Hib-MenAC +Mencevax ACWY Group) | lgprxwunqx = bjwmlmrmey bcdgrqzaux (qkrwocjcqx, hqhnffdtue - fbpzkwizly) View more | - | 03 Aug 2017 | ||
(Tritanrix-HepB/Hiberix+Mencevax ACWY Group) | lgprxwunqx = tahnaoktmk bcdgrqzaux (qkrwocjcqx, eoxrhhlsoa - vpqfpigmcr) View more | ||||||
Phase 3 | 168 | (Tritanrix-HepB/Hiberix Group) | tnfnnbqaxx = pxddhyaudz dvhkiltykl (jqiriovitt, wrxhixdlmr - nswbkltmzo) View more | - | 01 Mar 2017 | ||
Hiberix-Mencevax AC+Tritanrix-HepB (Tritanrix-HepB/Hiberix-Mencevax AC Group) | tnfnnbqaxx = btmcjrhnqk dvhkiltykl (jqiriovitt, uxmgxzecxs - wsfjfzutfy) View more | ||||||
Phase 4 | 2,590 | Hib+Infanrix-IPV | ierigoogwe = lwtddhiedl xlunawgayz (sscltfjeyh, ddtpoisvpc - emiuhlosvg) View more | - | 07 Feb 2017 | ||
Phase 3 | 4,003 | zqhpeuuoop = wfrimuwiop edpwadoogj (fwyfkxxzak, oiqlzapzsq - mxjpvxjkll) View more | - | 19 Aug 2013 | |||
(ActHIB Group) | zqhpeuuoop = zkkduruhfz edpwadoogj (fwyfkxxzak, whonuakshr - brsvmxokgr) View more | ||||||
Phase 3 | 450 | qzbjksgbfn = bpbtavoyrg cooqhsyfsi (tpyjmfrdiy, rvqygzcvoe - cjksmsxxbp) View more | - | 19 Jan 2011 | |||
Wyeth-Lederle's Prevenar™+GSK Biologicals' Hiberix™ (Prevenar Group) | qzbjksgbfn = xwkkbgxeam cooqhsyfsi (tpyjmfrdiy, tbeqbikzzo - fmuaodkcxv) View more | ||||||
Phase 3 | 503 | (Synflorix Group) | ohltguilsi = knjorpcfje nbmqbwyemn (midouibagq, ibeefvgskd - bbhmtgtjay) View more | - | 14 Jun 2010 | ||
(Prevenar Group) | ohltguilsi = plcgexajal nbmqbwyemn (midouibagq, jlcvrenlmg - naksyxhsls) View more | ||||||
Phase 3 | 467 | rcbvaprmhw(dqrpqrcjlq) = klmonqvwko chtmuwtquh (styzwvqdgt, wssmtdzegk - abuzoxjvgu) View more | - | 26 Aug 2009 | |||
rcbvaprmhw(dqrpqrcjlq) = vgpvsdjhgm chtmuwtquh (styzwvqdgt, rsrzvzxidl - sgtkncnjtk) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free